Morphological and functional characteristics of models of experimental myocardial injury induced by isoproterenol

General Physiology and Biophysics

Volumn 31, Issue 2, 2012, Pages 141-151

  Nichtova, Zuzana ^a,b   Novotova, Marta ^a   Kralova, Eva ^b   Stankovicova, Tatiana ^b  

^a INSTITUTE OF MOLECULAR PHYSIOLOGY AND GENETICS   (Slovakia)

^b Physics and Informatics   (Slovakia)

Author keywords

Electrocardiogram; Heart; Hemodynamic; Isoproterenol; Ultrastructure

Indexed keywords

ISOPRENALINE;

CHRONIC DRUG ADMINISTRATION; CLASSIFICATION; ENERGY TRANSFER; EXPERIMENTAL MODEL; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE EXCITABILITY; HEART MUSCLE INJURY; HEART VENTRICLE CONTRACTILITY; HEART VENTRICLE HYPERTROPHY; HUMAN; MORPHOLOGY; NONHUMAN; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; HEART CONDUCTION SYSTEM; HUMANS; ISOPROTERENOL; MYOCARDIAL CONTRACTION; MYOCARDIUM; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84862536365     PISSN: 02315882     EISSN: 13384325     Source Type: Journal    
DOI: 10.4149/gpb_2012_015     Document Type: Review

References (93)

1. Abdellatif M. (2010): The role of microRNA-133 in cardiac hypertrophy uncovered. Circ. Res. 106, 16-18 http://dx.doi.org/10.1161/CIRCRESAHA.109.212183
2. Angert D., Beretta R. M., Kubo H., Zhang H., Chen X., Wang W., Ogorek B., Barbe M., Houser S. R. (2011): Repair of the injured adult heart involves new myocytes potentially derived from resident cardiac stem cells. Circ. Res. 108, 1226-1237 http://dx.doi.org/10.1161/CIRCRESAHA.110.239046
3. Armoundas A. A., Wu R., Juang G., Marban E., Tomaselli G. F. (2001): Electrical and structural remodeling of the failing ventricle. Pharmacol. Ther. 92, 213-230 http://dx.doi.org/10.1016/S0163-7258 (01) 00171-1
4. Baillard C., Mansier P., Ennezat P. V., Mangin L., Medigue C., Swynghedauw B., Chevalier B. (2000): Converting enzyme inhibition normalizes QT interval in spontaneously hypertensive rats. Hypertension 36, 350-354
5. Bénitah J. P. (2002): Altered communication between L-type calcium channels and ryanodine receptors in heart failure. Fron. Biosi. 7, 263-275
6. Benjamin I. J., Jalil J. E., Tan L. B., Cho K., Weber K. T., Clark W. A. (1989): Isoproterenol-induced myocardial fibrosis in relation to myocyte. Circ. Res. 65, 657-670
7. Bestetti R. B., Ramos C. P., Figuerêdo-Silva J., Sales-Neto V. N., Oliveira J. S. (1987): Ability of the electrocardiogram to detect myocardial lesions in isoproterenol induced rat cardiomyopathy. Cardiovasc. Res. 21, 916-921 http://dx.doi.org/10.1093/cvr/21.12.916
8. Bestetti R. B., Oliveira J. S. (1990): The surface electrocardiogram: a simple reliable method for detecting overt and latent hearts disease in rats. Braz. J. Med. Biol. 23, 1213-1222
9. Boluyt M. O., Long X., Eschenhagen T., Mende U., Schmitz W., Crow M. T., Lakatta E. G. (1995): Isoproterenol infusion induces alterations in expression of hypertrophy-associated genes in rat heart. Am. J. Physiol. 269, H638-647
10. Bristow M. R. (2000): Beta adrenerenergic receptor blockade in chronic heart failure. Circulation 101, 558-569
11. Cannell M. B., Cheng H., Lederer W. J. (1995): The control of calcium repase in heart muscle. Science 268, 1045-1049 http://dx.doi.org/10.1126/ science.7754384
12. Cannell M. B., Crossman D. J., Soeller C. (2006): Effect of changes in action potential spike configuration, junctional sarcoplasmic reticulum micro-architecture and altered t-tubule structure in human heart failure. J. Muscle Res. Cell. Motility 27, 297-306 http://dx.doi.org/10.1007/s10974-006- 9089-y
13. Chagoya de Sánchez V., Hernández-Munoz R., López-Barrera F., Yanez L., Vidrio S., Suárez J., Cota-Garza M. D., Aranda-Fraustro A., Cruz D. (1997): Sequential changes of energy metabolism and mitochondrial function in myocardial infarction induced by isoproterenol in rats: a long-term and integrative study. Can. J. Physiol. Pharmacol. 75, 1300-1311 http://dx.doi.org/10.1139/y97-154
14. Chorvatova A., Hart G., Hussain M. (2004): Na+/Ca2+ exchange current (I (Na/Ca)) and sarcoplasmic reticulum Ca2+ release in catecholamine-induced cardiac hypertrophy. Cardiovasc. Res. 61, 278-287 http://dx.doi.org/10.1016/j. cardiores.2003.11.019
15. Cibllis M. S., Hirstat C. S. (1980): Human stress cardiomyopathy. Human Pathol. 11, 123-132 http://dx.doi.org/10.1016/S0046-8177 (80) 80129-8
16. Clark W. A., Rudnick S. J., LaPres J. J., Lesch M., Decker R. S. (1991): Hypertrophy of isolated adult feline heart cells following betaadrenergic- induced beating. Am. J. Physiol. 261, C530-542
17. Colucci W. S., Sawyer D. B., Singh K., Communal C. (2000): Adrenergic overload and apoptosis in heart failure: implications for therapy. J. Card. Fail. 2, 1-7
18. Crossman D. J., Ruygrok P. N., Soeller C., Cannell M. B. (2011): Changes in the organization of excitation-contraction coupling structures in failing human heart. PLoS One 6, e17901 http://dx.doi.org/10.1371/journal.pone.0017901
19. Dhalla N. S., Saini-Chohan H. K., Rodriguez-Leyva D., Elimban V., Dent M. R., Tappia P. S. (2009): Subcellular remodelling may induce cardiac dysfunction in congestive heart failure. Cardiovasc. Res. 81, 429-438 http://dx.doi.org/10. 1093/cvr/cvn281
20. Dhingra R., Pencina M. J., Wang T. J., Nam B. H., Benjamin E. J., Levy D., Larson M. G., Kannel W. B., D'Agostino R. B. Sr, Vasan R. S. (2006): Electrocardiographic QRS duration and the risk of congestive heart failure: the Framingham Heart Study. Hypertension 47, 861-867 http://dx.doi.org/10.1161/01. HYP.0000217141.20163.23
21. Dresel P. E., Hart M. C., Strömbland B. C. R. (1963): Cardiac arrhythmias induced by injection of isoproterenol into the coronary arteries. J. Pharmacol. Exp. Ther. 140, 67-75
22. Dudnáková T. V., Lakomkin V. L., Tsyplenkova V. G., Shekhonin B. V., Shirinsky V. P., Kapelko V. I. (2003): Alterations in myocardial ultrastructure and protein expression afer a single injection of isoproterenol. Mol. Cell. Biochem. 252, 173-181 http://dx.doi.org/10.1023/A: 1025579624695
23. Ellison G. M., Torella D., Karakikes I., Purushothaman S., Curcio A., Gasparri C., Indolfi C., Cable N. T., Goldspink D. F., Nadal-Ginard B. (2007): Acute β-adrenergic overload produces myocyte damage through calcium leakage from ryanodine receptor 2 but spares cardiac stem cells. J. Biol. Chem. 282, 11397-11409 http://dx.doi.org/10.1074/jbc. M607391200
24. Ennis I. L., Escuredo E. M., Console G. M., Camihort G., Dumm C. G., Seidler R. W., Camilión de Hurtado M. C., Cingolani H. E. (2003): Regression of isoproterenol-induced cardiac hypertrophy by Na+/H+ exchanger inhibition. Hypertension 41, 1324-1329 http://dx.doi.org/10.1161/01. HYP.0000071180.12012.6E
25. Feng W., Li W. (2009): The study of ISO induced heart failure rat model. Exp. Mol. Pathol. 88, 299-304 http://dx.doi.org/10.1016/j.yexmp. 2009.10.011
26. Ferreira A. J., Oliveira T. L., Castro M. C., Almeida A. P., Castro C. H., Caliari M. V., Gava E., Kitten G. T., Santos R. A. (2007): Isoproterenol-induced impairment of heart function and remodeling are attenuated by the nonpeptide angiotensin-(1-7) analogue AVE 0991. Life Sci. 81, 916-923 http://dx.doi.org/10.1016/j.lfs.2007.07.022
27. Fowler M. B., Laser J. A., Hopkins G. L., Minobe W., Bristow MR. (1986): Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor downregulation and subsensitivity to agonist response. Circulation 74, 1290-1302 http://dx.doi.org/10.1161/01. CIR.74.6.1290
28. Goldspink D. E., Burniston J. G., Ellison G. M., Clark W. A., Tan L. B. (2004): Catecholamine-induced apoptosis and necrosis in cardiac and skeletal myocytes of the rat in vivo: the same or separate death pathways? Exp. Physiol. 89, 407-416 http://dx.doi.org/10.1113/expphysiol.2004.027482
29. Golomb E., Abassi Z. A., Cuda G., Stylianou M., Panchal V. R., Trachewsky D., Keiser H. R. (1994): Angiotensin II maintains, but does not mediate, isoproterenol-induced cardiac hypertrophy in rats. Am. J. Physiol. 267, H1496-1506
30. Gomez A. M., Guatimosim S., Dilly K. W., Vassort G., Lederer W. J. (2001): Heart failure afer myocardial infarction: altered excitation-contraction coupling. Circulation 104, 688-693 http://dx.doi.org/10.1161/hc3201.092285
31. Grimm D., Elsner D., Schunkert H., Pfeifer M., Griese M., Bruckschlegel G., Muders F., Riegger G. A. J., Kromer E. P. (1998): Development of heart failure following isoproterenol administration in the rat: role of the renin - angiotensin system. Cardiovasc. Res. 37, 91-100 http://dx.doi.org/10.1016/S0008- 6363 (97) 00212-5
32. Haunstetter A., Izumo S. (2000): Toward antiapoptosis as a new treatment modality. Circ. Res. 86, 371-376
33. Heijman J., Volders P. G., Westra R. L., Rudy Y. (2011): Local control of β-adrenergic stimulation: Effects on ventricular myocyte electrophysiology and Ca (2+)-transient. J. Mol. Cell. Cardiol. 50, 863-871 http://dx.doi.org/10. 1016/j.yjmcc.2011.02.007
34. Horiuchi-Hirose M., Kashihara T., Nakada T., Kurebayashi N., Shimojo H., Shibazaki T., Sheng X., Yano S., Hirose M., Hongo M., Sakurai T., Moriizumi T., Ueda H., Yamada M. (2010): Decrease in the density of t-tubular L-type Ca2+ channel currents in failing ventricular myocytes. Am. J. Physiol. 300, 978-988
35. Houser S. R. (2001): Reduced abundance of transverse tubules and L-type calcium channels: another cause of defective contractility in failing ventricular myocytes. Cardiovasc. Res. 49, 253-256 http://dx.doi.org/10.1016/ S0008-6363 (00) 00305-9
36. Kahn D. S., Rona G., Chappel C. I. (1969): Isoproterenol-induced cardiac necrosis. Ann. NY. Acad. Sci. 156, 285-293 http://dx.doi.org/10.1111/j.1749- 6632.1969.tb16735.x
37. Kannel W. B. (1998): Epidemiology of cardiac hypertrophy. In: Lef Ventricular Hypertrophy. (Ed. D. J. Sheridan), pp. 1-10, Churchill Livingstone, London
38. Khan M. G. (2003): ECG and its evaluation. Grada, Prague, 340 (in Czech)
39. Korb G., Totovič V. (1967): Elektronmikroskopische untersuchungen über fruhvenderungen im zentrum und in der peripherie experimenteller herzinfarkte. Virch. Arch. Anat. 342, 85-96 http://dx.doi.org/10.1007/BF00956851
40. Králová E., Mokrán T., Murín J., Stankovičová T. (2008): Electrocardiography in two models of isoproterenol-induced lef ventricular remodeling. Physiol. Res. 57, 83-89
41. Králová E., Mikušová A., Novotová M., Stankovičová T. (2009): Myocardial remodeling induced by repeated doses of isoproterenol. Physiol. Res. 58, P14
42. Krenek P., Klimas J., Kroslakova M., Gazova A., Plandorova J., Kucerova D., Fecenkova A., Svec P., Kyselovic J. (2006): Increased expression of endothelial nitric oxide synthase and caveolin-1 in the aorta of rats with isoproterenol-induced cardiac hypertrophy. Can. J. Physiol. Pharmacol. 84, 1245-1250 http://dx.doi.org/10.1139/y06-073
43. Krenek P., Kmecova J., Kucerova D., Bajuszova Z., Musil P., Gazova A., Ochodnicky P., Klimas J., Kyselovic J. (2009): Isoproterenolinduced heart failure in the rat is associated with nitric oxidedependent functional alterations of cardiac function. Eur. J. Heart Fail. 11, 140-146 http://dx.doi.org/10.1093/eurjhf/hfn026
44. Landmesser U., Drexler H. (2007): Update on inotropic therapy in the management of acute heart failure. Curr. Treat. Options Cardiovasc. Med. 9, 443-449 http://dx.doi.org/10.1007/s11936-007-0039-9
45. Leenen F. H., White R., Yuan B. (2001): Isoproterenol-induced cardiac hypertrophy: role of circulatory versus cardiac reninangiotensin system. Am. J. Physiol. 281, H2410-2416
46. Lijnen P. J., Petrov V. V., Fagard R. H. (2000): Induction of cardiac fibrosis by angiotensin II. Methods Find. Exp. Clin. Pharmacol. 22, 709-723 http://dx.doi.org/10.1358/mf.2000.22.10.802287
47. Limbird L. E., Voughan D. E. (1999): Augmenting beta receptors hastens relaxation and mediates phosphorylation in the heart: short-term gains offset by long-term of phospholamban, troponin I, and C-protein in pains? Proc. Natl. Acad. Sci. U. S. A. 96, 7125-7127 http://dx.doi.org/10.1073/pnas.96.13.7125
48. Linck B., Bokník P., Baba H. A., Eschenhagen T., Haverkamp U., Jäckel E., Jones L. R., Kirchhefer U., Knapp J., Läer S., Müller F. U., Schmitz W., Scholz H., Syska A., Vahlensieck U., Neumann J. (1998): Long-term beta adrenoceptor-mediated alteration in contractility and expression of phospholamban and sarcoplasmic reticulum Ca2+-ATPase in mammalian ventricle. J. Pharmacol. Exp. Ther. 286, 531-538
49. López-López J. R., Shacklock P. S., Balke C. W., Wier W. G. (1995): Local calcium transients triggered by single L-type calcium channel currents in cardiac cells. Science 268, 1042-1045 http://dx.doi.org/10.1126/ science.7754383
50. Ma X., Song Y., Chen C., Fu Y., Shen Q., Li Z., Zhang Y. (2011): Distinct actions of intermittent and sustained β-adrenergic receptor stimulation on cardiac remodeling. Sci. China Life Sci. 54, 493-501 http://dx.doi.org/10.1007/ s11427-011-4183-9
51. Mathew J., Sleight P., Lonn E., Johnstone D., Pogue J., Yi Q., Bosch J., Sussex B., Probstfield J., Yusuf S., Heart Outcomes Prevention Evaluation (HOPE) Investigators (2001): Reduction of cardiovascular risk by regression of electrocardiographic markers of lef ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 104, 1615-1621 http://dx.doi.org/10.1161/hc3901.096700
52. Mészáros J., Khananshvili D., Hart G. (2001): Mechanisms underlying delayed aferdepolarizations in hypertrophied lef ventricular myocytes of rats. Am. J. Physiol. 281, 903-914
53. Mészáros J., Levai G. (1990): Ultrastructural and electrophysiological alterations during the development od catecholamine-induced cardiac hypertrophy and failure. Acta Biol. Hung. 41, 289-307
54. Mészáros J., Pasztor B. (1995): Effect of ouabain in catecholamineinduced cardiac hypertrophy. Acta Physiol. Hung. 1, 55-62
55. Mikušová A., Králová E., Tylková L., Novotová M., Stankovičová T. (2009): Myocardial remodeling induced by repeated low doses of isoproterenol. Can. J. Physiol. Pharmacol. 87, 641-651 http://dx.doi.org/10.1139/Y09-053
56. Moalic J. M., Charlemagne D., Mansier P., Chevalier B., Swynghedauw B. (1993a): Cardiac hypertrophy and failure-a disease of adaptation. Modifications in membrane proteins provide a molecular basis for arrhythmogenicity. Circulation 87, IV21-26
57. Moalic J. M., Bourgeois F., Mansier P., Machida C. A., Carré F., Chevalier B., Pitarque P., Swynghedauw B. (1993b): Beta 1 adrenergic receptor and G alpha s mRNAs in rat heart as a function of mechanical load and thyroxine intoxication. Cardiovasc. Res. 27, 231-237 http://dx.doi.org/10.1093/cvr/27.2. 231
58. Nagano M., Higaki J., Nakamura F., Higashimori K., Nagano N., Mikami H., Ogihara T. (1992): Role of cardiac angiotensin II in isoproterenol induced lef ventricular hypertrophy. Hypertension 19, 708-712
59. Nichtová Z., Králová E., Novotová M., Stankovičová T. (2010): Ultrastructural and functional myocardial changes induced by 3weeks lasting addition of low doses of isoproterenol to rats. Physiol. Res. 59, 26P
60. Novotová M., Tylková L., Zahradník I., Zahradníková A. (2006): Ultrastructural changes in cardiac cells afer a single application of isoproterenol. New Frontiers in Basic Cardiovascular Research. Debrecen, Hungary 5-8 Oct. Program and abstracts L 13, 35
61. Ocaranza M. P., Diaz-Araya G., Chiong M., Munoz D., Riveros J. P., Ebensperger R., Sabat S., Irarrázaval P., Jalil J. E., Lavandero S. (2002): Isoproterenol and angiotensin I-converting enzyme in lung, lef ventricle and plasma during myocardial hypertrophy and fibrosis. J. Cardiovasc. Pharmacol. 40, 246-254 http://dx.doi.org/10.1097/00005344-200208000-00010
62. Oikarinen L., Nieminen M. S., Viitasalo M., Toivonen L., Jern S., Dahlof B., Devereux R. B., Okin P. M., Life study investigators (2004): QRS duration and QT interval predict mortality in hypertensive patients with lef ventricular hypertrophy: Losartan intervention for endpoint reduction in hypertension study. Hypertension 43, 1029-1034 http://dx.doi.org/10.1161/01. HYP.0000125230.46080. c6
63. Okin P. M., Devereux R. B., Jern S., Kjeldsen S. E., Julius S., Nieminen M. S., Snapinn S., Harris K. E., Aurup P., Edelman J. M., Dahlof B. (2003): Regression of electrocardiographic lef ventricular hypertrophy by losartan versus atenolol: the losartan intervention for endpoint reduction in hypertension (life) study. Circulation 108, 684-690 http://dx.doi.org/10.1161/ 01. CIR.0000083724.28630. C3
64. Okin P. M., Nieminen M. S., Jern S., Oikarinen L., Viitasalo M., Toivonen L., Kjeldsen S. E., Julius S., Snapinn S., Dahlof B. (2004): Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients. Hypertension 44, 48-54 http://dx.doi.org/10.1161/01. HYP.0000132556.91792.
65. Osadchii O. E. (2007): Cardiac hypertrophy induced by sustained β-adrenergic receptor activation: pathophysiological aspects. Heart Fail. Rev. 12, 66-86 http://dx.doi.org/10.1007/s10741-007-9007-4
66. Ozaki M., Kawashima S., Yamashita T., Hirase T., Ohashi Y., Inoue N., Hirata K., Yokoyoma M. (2002): Overexpression of endothelial nitric oxide synthase attenuates cardiac hypertrophy induced by chronic isoproterenol infusion. Circulation 66, 851-856 http://dx.doi.org/10.1253/circj.66.851
67. Pick R., Jalil J. E., Janicki J. S., Weber K. T. (1989): The fibrillar nature and structure of isoproterenol-induced myocardial fibrosis in the rat. Am. J. Pathol. 134, 365-371
68. Poupa O. (1962): On physiological adaptations. Cas. Lek. Cesk. 101, 776-781 (in Czech)
69. Raab W. (1960): Key position of catecholamines in functional and degenerative cardiovascular pathology. Am. J. Cardiol. 5, 571-578 http://dx.doi.org/10.1016/0002-9149 (60) 90121-1
70. Rajadurai M., Prince P. S. (2007): Preventive effect of narginin on cardiac mitochondrial enzymes during isoproterenol-induced myocardial infarction in rats: a transmission electron microscopic study. J. Biochem. Mol. Toxicol. 21, 354-361 http://dx.doi.org/10.1002/jbt.20203
71. Ribeiro D. A., Buttros J. B., Oshima C. T. F., Bergamaschi C. T., Campos R. R. (2009): Ascorbic acid prevents acute myocardial infarction induced by isoproterenol in rats: role of inducible nitric oxide synthase production. J. Mol. Hist. 40, 99-105 http://dx.doi.org/10.1007/s10735-009-9218-1
72. Rona G., Chappel C. I., Balazs T., Gaudry R. (1959): An infarct-like myocardial lesion and other toxic manifestations produced by isoproterenol in the rat. AMA Arch. Path. 67, 443-455
73. Rona G., Kahn D. S., Chappel C. I. (1961): Study on the healing of cardiac necrosis in the rat. Am. J. Pathol. 39, 473-489
74. Rona G. (1985): Catecholamine cardiotoxicity. J. Mol. Cell. Cardiol. 17, 291-300 http://dx.doi.org/10.1016/S0022-2828 (85) 80130-9
75. Sethi R., Saini H. K., Guo X., Wang X., Elimban V., Dhalla N. S. (2007): Dependence of changes in beta-adrenoceptor signal transduction on type and stage of cardiac hypertrophy. J. Appl. Physiol. 102, 978-984 http://dx.doi.org/10. 1152/japplphysiol.00921.2006
76. Sia Y. T., Parker T. G., Tsoporis J. N., Liu P., Adam A., Rouleau J. L. (2002): Long-term effects of carvedilol on lef ventricular function, remodeling, and expression of cardiac cytokines afer large myocardial infarction in the rat. J. Cardiovasc. Pharmacol. 39, 73-87 http://dx.doi.org/10.1097/00005344- 200201000-00009
77. Soltysinska E., Thiele S., Olesen S. P., Osadchii O. E. (2011a): Chronic sympathetic activation promotes downregulation of β-adrenoceptor-mediated effects in the guinea pig heart independently of structural remodeling and systolic dysfunction. Pflügers Arch. 462, 529-543 http://dx.doi.org/10. 1007/s00424-011-1005-7
78. Soltysinska E., Olesen S. P., Osadchii O. E. (2011b): Myocardial structural, contractile and electrophysiological changes in the guinea-pig heart failure model induced by chronic sympathetic activation. Exp. Physiol. 96, 647-663 http://dx.doi.org/10.1113/expphysiol.2011.058503
79. Song L. S., Sobie E. A., McCulle S., Lederer W. J., Balke C. W., Cheng H. (2006): Orphaned ryanodine receptors in the failing heart. Proc. Natl. Acad. Sci. U. S. A. 103, 4305-4310 http://dx.doi.org/10.1073/pnas.0509324103
80. Strand A. H., Gudmundsdottir H., Os I., Smith G., Westheim A. S., Bjørnerheim R., Kjeldsen S. E. (2006): Arterial plasma noradrenaline predicts lef ventricular mass independently of blood pressure and body build in men who develop hypertension over 20 years. J. Hypertens. 24, 905-913 http://dx.doi.org/10.1097/01.hjh.0000222761.07477.7b
81. Suzuki M., Ohte M., Wang Z-M., Williams Jr. D. L., Little W. C., Cheng Ch.-P. (1998): Altered inotropic response of endothelin-1 in cardiomyocytes from rats with isoproterenol-induced cardiomyopathy. Cardiovasc. Res. 39, 589-595 http://dx.doi.org/10.1016/S0008-6363 (98) 00166-7
82. Swynghedauw B. (2005): The acquired long QT during cardiac hypertrophy. Origin, incidence and significance. Bull. Acad. Natl. Med. 1, 31-40
83. Tang Ch., Yang J., Wu L. L., Dong L. W., Liu M. S. (1998). Phosphorylation of β-adrenergic receptor leads to its redistribution in rat heart during sepsis. Am. J. Physiol. 274, R1078-1086
84. Tang M., Zhang X., Li Y., Guan Y., Ai X., Szeto C., Nakayama H., Zhang H., Ge S., Molkentin J. D., Houser S. R., Chen X. (2010): Enhanced basal contractility but reduced excitation-contraction coupling efficiency and beta-adrenergic reserve of hearts with increased Cav1.2 activity. Am. J. Physiol. Heart. Circ. Physiol. 299, H519-528 http://dx.doi.org/10.1152/ajpheart. 00265.2010
85. Tang Q., Taylor P. B. (1984): Regression of isoproterenol-induced cardiac hypertrophy. Can. J. Physiol. Pharmacol. 62, 1141-1146 http://dx.doi.org/10. 1139/y84-191
86. Teerlink J. R., Pfeffer J. M., Pfeffer M. A. (1994): Progressive ventricular remodeling in response to diffuse isoproterenol-induced myocardial necrosis in rats. Circ. Res. 75, 105-113
87. Turek Z., Kalus M., Poupa O. (1966): The effect of isoprenaline pretreatment on the size of acute myocardial necrosis induced by the same drug. Physiol. Bohemoslov. 15, 353
88. Verdecchia P., Schillaci G., Borgioni C., Ciucci A., Gattobigio R., Zampi I., Reboldi G., Porcellati C. (1998): Prognostic significance of serial changes in lef ventricular mass in essential hypertension. Circulation 97, 48-54
89. Zhang G. X., Kimura S., Nishiyama A., Shokoji T., Rahman M., Yao L., Nagai Y., Fujisawa Y., Miyatake A., Abe Y. (2005): Cardiac oxidative stress in acute and chronic isoproterenol-infused rats. Cardiovasc. Res. 65, 230-238 http://dx.doi.org/10.1016/j.cardiores.2004.08.013
90. Zhang Y., Li Y., Liu B., Wei R., Wang D., Tan X., Bu D., Pang Y., Tang C. (2007): Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol. Acta Pharmacol. Sin. 28, 36-43 http://dx.doi.org/10. 1111/j.1745-7254.2007.00485.x
91. Zierhut W., Zimmer H. G. (1989): Significance of myocardial alpha-and beta-adrenoceptors in catecholamine-induced cardiac hypertrophy. Circ. Res. 65, 1417-1425
92. Zimmer H. G. (1997): Catecholamine-induced cardiac hypertrophy: significance of proto-oncogene expression. J. Mol. Med. 75, 849-859 http://dx.doi.org/10.1007/s001090050176
93. Zou Y., Komuro I., Yamazaki T., Kudoh S., Uozumi H., Kadowaki T., Yazaki Y. (1999): Both Gs and Gi proteins are critically involved in isoproterenol-induced cardiomyocyte hypertrophy. J. Biol. Chem. 274, 9760-9770 http://dx.doi.org/10.1074/jbc.274.14.9760